Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: A study in patients with disseminated non-seminomatous testicular cancer

British Journal of Cancer

Volumn 75, Issue 3, 1997, Pages 432-435

  De Wit, R ^a   Sylvester, R ^b   Tsitsa, C ^b   De Mulder, P H M ^c   Sleyfer, D T ^d   Ten Bokkel Huinink, W W ^e   Kaye, S B ^f   Van Oosterom, A T ^g   Boven, E ^h   Vermeylen, K ^b   Stoter, G ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^g ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Half life; Prognosis; Testicular cancer; Tumour markers

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; TUMOR MARKER; VINBLASTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HALF LIFE TIME; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TESTIS CANCER; TREATMENT FAILURE;

EID: 8044240914     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.71     Document Type: Article

References (21)

1. Aass N, Klepp O, Cavallin-Stahl E, Dahl O, Wicklund H, Unsgaard B, Baldetorp L, Ahlström S and Fossa SD (1991) Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 9: 818-826
2. Bajorin D, Katz A, Chan E, Geller N, Vogelzang N and Bosl GJ (1988) Comparison of criteria for assigning germ cell tumour patients to 'good risk' and 'poor risk' studies. J Clin Oncol 6: 786-792
3. Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S and Greco FA for the Southeastern Cancer Study Group (1986) Prognostic factors for favourable outcome in disseminated germ cell tumours. J Clin Oncol 4: 400-407
4. Bosl GJ, Geller NL, Cirrincione C, Vogelzang NJ, Kennedy BJ, Whitmore JR WF, Vugrin D, Scher H, Nisselbaum J and Golbey RB (1983) Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43: 3403-3407
5. Droz JP, Kramar A, Ghosn M, Piot G, Rey A, Theodore C, Wibault P, Court BH, Perrin JL, Travagli JP, Bellet D, Caillaud JM, Pico JL and Hayat M (1988) Prognostic factors in advanced nonseminomatous testicular cancer. Cancer 62: 564-568
6. Hitchins RN, Newlands ES, Smith DB, Begent RHJ, Rustin GJS and Bagshawe KD (1989) Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis. Br J Cancer 59: 236-242
7. Kohn J (1979) The value of apparent half-life assay of alpha-1-fetoprotein in the management of testicular teratoma. In Carcino-Embryonic Proteins, Chemistry, Biology, Clinical Applications, Lehman FG, (ed.) pp. 383-386, Elsevier/North Holland Biomedical Press: Amsterdam
8. Levi JA, Thomson D, Sandeman T, Tattersall M, Raghavan D, Byrne M, Gill G, Harvey V, Burns I and Snyder R (1988) A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: role of maintenance and long-term follow-up. J Clin Oncol 6: 1154-1160
9. Mead GM, Stenning SP, Parkinson MC, Horwich A, Fosså SD, Wilkinson PM, Kaye SB, Newlands ES and Cook PA for the Medical Research Council Testicular Tumour Working Party (1992) The second medical research council study of prognostic factors in nonseminomatous germ cell tumours. J Clin Oncol 10: 85-94
10. Medical Research Council Working Party on Testicular Tumours (1985) Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Lancet 1: 8-11
11. Motzer RJ, Mazumdar M, Gulati SC, Bajorin DF, Lyn P, Vlamis V and Bosl GJ (1993) Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumours. J Natl Cancer Inst 85: 1828-1835
12. Peckham MJ, Horwich A, Easton DF and Hendry WF (1988) The management of advanced testicular teratoma. Br J Urol 62: 63-68
13. Roth BJ, Greist A, Kubilis PS, Williams SD and Einhorn LH (1990) Cisplatin-based combination chemotherapy for disseminated germ cell tumours: long-term follow-up. J Clin Oncol 6: 1239-1247
14. Stevens M and Horwich A (1995) Prognostic significance of serum marker half-life in metastatic testicular teratoma. J Clin Oncol 13: 87-92
15. Stoter G and Sylvester R (1990) Prognostic factors in disseminated testicular cancer: the EORTC GU Group study results. J Cancer Res Clin Oncol 116(suppl.): 950
16. Stoter G, Sylvester R, Sleijfer DT, Ten Bokkel Huinink WW, Kaye SB, Jones WG, Van Oosterom AT, Vendrik CPJ, Spaander P and DE Pauw M (1987) Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results form a European Organization for Research on Treatment of Cancer multi-institutional phase III study. Cancer Res 47: 2714-2718
17. Stoter G, Koopman A, Vendrik CP, Struyvenberg A, Sleijfer DTH, Willemse PHB, Schraffordt Koops H, Van Oosterom AT, Ten Bokkel Huinink WW and Pinedo HM (1989) Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 7: 1099-1104
18. Stoter G, Kaye S, Jones W, Ten Bokkel Huinink W, Sleijfer D, Splinter T, Van Oosterom A, DE Pauw M and Sylvester R (1991) Cisplatin (P) and VP16 (E) +/-bleomycin (B), BEP vs. EP in good risk patients with disseminated nonseminomatous testicular cancer: a randomised EORTC GU Group study. Onkologie 14(suppl.4): 17
19. Toner GC, Geller NL, Tan C, Nisselbaum J and Bosl GJ (1990) Serum tumour marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumours. Cancer Res 50: 5904-5910
20. Vogelzang NJ, Lange PH, Goldman A, Vessela RH, Fraley EE and Kennedy BJ (1982) Acute changes of alpha-fetoprotein and human chononic gonadotropin during induction chemotherapy of germ cell tumours. Cancer Res 42: 4855-4861
21. Wit de R, Stoter G, Sleijfer DTH, Mulder de PHM, Bokkel Huinink Ten WW, Spaander PJ, Pauw de M and Sylvester R (1995) Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma: a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71: 1311-1314